申请人:Glaxo Group Limited
公开号:US04496579A1
公开(公告)日:1985-01-29
Compounds are disclosed of general formula ##STR1## where R is H, C.sub.1-6 alkyl optionally substituted by C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl or alkynyl, C.sub.3-7 cycloalkyl, aralkyl or --CHO and the physiologically acceptable salts thereof. The compounds have selective .alpha..sub.2 -adrenoreceptor antagonist action and are indicated as potentially useful for the treatment or prevention of migraine, thrombosis, diabetes, obesity, hypertension, constipation, paralytic ileus, senile dementia and analepsis, and for use in appetite suppression and for the treatment of depression; they may be formulated as pharmaceutical compositions in conventional manner. The compounds may be prepared, for example, by amination of a compound of formula ##STR2## where X is a leaving group such as halogen or a hydrocarbylsulphonyloxy group.
本发明公开了一般式为##STR1##的化合物及其生理上可接受的盐,其中R为H,C.sub.1-6烷基,该烷基可以被C.sub.3-7环烷基,C.sub.3-6烯基或炔基,C.sub.3-7环烷基,芳基烷基或--CHO取代。这些化合物具有选择性α.sub.2-肾上腺素受体拮抗作用,并被认为可能用于治疗或预防偏头痛、血栓形成、糖尿病、肥胖症、高血压、便秘、麻痹性肠梗阻、老年性痴呆和复苏,以及用于食欲抑制和治疗抑郁症;它们可以按照常规方法制成药物组成物。这些化合物可以通过化合物##STR2##的氨化反应制备,其中X是离去基,例如卤素或烃基磺酰氧基。